产品说明书

SCH-23390 HCl

Print
Chemical Structure| 125941-87-9 同义名 : R-(+)-SCH-23390 hydrochloride;SCH 23390 (hydrochloride);SCH-23390 hydrochloride
CAS号 : 125941-87-9
货号 : A805808
分子式 : C17H19Cl2NO
纯度 : 98%
分子量 : 324.245
MDL号 : MFCD00069249
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 30 mg/mL(92.52 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 28 mg/mL(86.35 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • D5 receptor

    D5 dopamine receptor, Ki:0.3 nM

  • D1 receptor

    D1 dopamine receptor, Ki:0.2 nM
描述 Dopamine receptors have been associated with many neurological disorders, including most notably Parkinson’s disease and schizophrenia. SCH 23390 is a highly potent and selective dopamine D1-like receptor antagonist with a Ki of 0.2 and 0.3 nM for the D1 and D5 dopamine receptor subtypes, respectively. SCH 23390 HCl is the hydrochloride form of SCH 23390. SCH 23390 also binds with high affinity to the 5-HT2 and 5-HT1C serotonin receptor subtypes[1]. Intra-DLS (dorsolateral striatum) microinfusion of SCH23390 (100 ng) or sulpiride both increased anxiety, indicated by increases in time spent in the enclosed maze arms in rats, while intra-DMS (dorsomedial striatum) microinfusion of SCH23390, sulpiride, or saline did not affect performance in a novelty preference test, indicated by greater time spent in a ‘novel’ maze arm compared to ‘non-novel’ arms[2]. In contextual fear conditioning and memory testing, SCH23390 (0.1 mg/kg) given before conditioning or before both conditioning and retrieval decreased freezing at retrieval, whereas SCH23390 given only before retrieval had no effect. SCH23390 (2.5 μg/0.5 uL) infused into dmPFC (dorsomedial prefrontal cortex) before conditioning decreased freezing at retrieval, while infusion of SCH23390 into NAc (nucleus accumbens) or VH (ventral hippocampus) had no effect[3].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.08mL

0.62mL

0.31mL

15.42mL

3.08mL

1.54mL

30.84mL

6.17mL

3.08mL
参考文献

[1]Bourne JA. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 2001;7(4):399‐414.

[2]Nguyen D, Alushaj E, Erb S, Ito R. Dissociative effects of dorsomedial striatum D1 and D2 receptor antagonism in the regulation of anxiety and learned approach-avoidance conflict decision-making. Neuropharmacology. 2019;146:222‐230.

[3]Stubbendorff C, Hale E, Cassaday HJ, Bast T, Stevenson CW. Dopamine D1-like receptors in the dorsomedial prefrontal cortex regulate contextual fear conditioning. Psychopharmacology (Berl). 2019;236(6):1771‐1782.